Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and <it>pgk</it> promoter: an <it>in vitro</it> and <it>in vivo</it> study

Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and <it>pgk</it> promoter: an <it>in vitro</it> and <it>in vivo</it> study

<p>Abstract</p> <p>Background</p> <p>Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Current therapies are insufficient, making HCC an intractable disease. Our previous studies confirmed that inhibition of protein phosphat...

Full description

Bibliographic Details
Main Authors: Li Wei, Li Dao-Ming, Chen Kai, Chen Zheng, Zong Yang, Yin Hong, Xu Ze-Kuan, Zhu Yi, Gong Fei-Ran, Tao Min
Format: Article
Language:English
Published: BMC 2012-11-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
AFP
Pgk
PP2A
Online Access:http://www.biomedcentral.com/1471-2407/12/547

Internet

http://www.biomedcentral.com/1471-2407/12/547

Similar Items